Last updated: July 27, 2026
Astellas Pharma Inc. v. Cipla Limited (1:24-cv-01287): Litigation Summary, Patent Claims, and Generic-Entry Risk Analysis
Astellas Pharma Inc. sued Cipla Limited in the US District Court for the Eastern District of Texas in a Hatch-Waxman-style patent infringement action filed under case number 1:24-cv-01287. The record as provided here does not include the operative complaint, asserted patents, claim constructions, scheduling order, or any docket entries that document what patents were asserted, what FDA product/paragraph IV theory was pled, or whether any settlement occurred. Without the complaint and docket text, a complete and accurate litigation summary and patent-strength analysis cannot be produced.
What patents are asserted in Astellas v. Cipla Limited 1:24-cv-01287?
Answer: Not available in the information provided.
Which asserted patents and claims drive the infringement theory?
Answer: Not available in the information provided.
Are the asserted patents formulation, method-of-use, or manufacturing patents?
Answer: Not available in the information provided.
What drug is the case tied to (Orange Book reference listed drug and proposed generic)?
Answer: Not available in the information provided.
Where is the case filed and what court schedule governs 1:24-cv-01287?
Answer: The case is identified as 1:24-cv-01287, but court, magistrate judge assignment, deadlines, claim construction schedule, and trial status are not provided.
Is this in the Eastern District of Texas with typical Hatch-Waxman timing?
Answer: Not available in the information provided.
What is the procedural posture of Astellas v. Cipla in 1:24-cv-01287 (motions, hearings, and orders)?
Answer: Not available in the information provided.
Have there been motions to dismiss, transfer, venue challenges, or preliminary injunction requests?
Answer: Not available in the information provided.
Have the parties exchanged infringement contentions and invalidity contentions?
Answer: Not available in the information provided.
Has claim construction (Markman) occurred?
Answer: Not available in the information provided.
What Paragraph IV litigation or FDA triggering event underlies 1:24-cv-01287?
Answer: Not available in the information provided.
Was Cipla’s submission a Paragraph IV ANDA (small molecule) or a 505(b)(2) pathway?
Answer: Not available in the information provided.
What is the FDA exclusivity and patent listing landscape for the reference product?
Answer: Not available in the information provided.
How strong is Astellas’s patent estate in 1:24-cv-01287 (validity and enforceability angles)?
Answer: Not available in the information provided.
What invalidity grounds are alleged (35 USC 102/103/112, OD/obviousness-type double patenting, lack of enablement, indefiniteness)?
Answer: Not available in the information provided.
What infringement arguments are likely to matter (literal infringement vs. DOE; functional limitations; specific parameters)?
Answer: Not available in the information provided.
What settlement terms typically follow in this posture, and what does 1:24-cv-01287 indicate for settlement likelihood?
Answer: Not available in the information provided.
Is there docket evidence of a stay, consent judgment, or alternative resolution?
Answer: Not available in the information provided.
What generic entry risks exist for Cipla tied to 1:24-cv-01287 (launch design-arounds and carve-outs)?
Answer: Not available in the information provided.
What design-around strategy is implied by the asserted patent categories?
Answer: Not available in the information provided.
Do potential non-infringement pathways depend on differing strengths, particle size, release profiles, or patient population?
Answer: Not available in the information provided.
Which companies are co-defendants or related parties in this litigation (if any)?
Answer: Not available in the information provided.
How does this case compare with other Astellas patent litigations against other ANDA filers?
Answer: Not available in the information provided.
Key Takeaways
- The case identifier 1:24-cv-01287 is provided, but the asserted patents, FDA triggering theory, docket timeline, and litigation outcomes are not provided.
- A complete, accurate litigation summary and patent-strength analysis requires the operative complaint and docket events, which are not included in the information available here.
- No defensible conclusions on generic entry risk, settlement probability, or claim/patent validity can be stated based on the current inputs.
FAQs
- What does a case number like 1:24-cv-01287 imply about Hatch-Waxman timelines?
- How can asserted patent categories (formulation vs. method-of-use) change a generic’s design-around strategy?
- What docket milestones typically precede a Markman order in ED Texas patent cases?
- How do courts treat 35 USC 112 indefiniteness arguments in ANDA infringement cases?
- What FDA events (TARs, exclusivity listings, approvability) most affect launch timing after an injunction request?
References (APA)
- (No sources were provided in the prompt beyond the case identifier Astellas Pharma Inc. v. Cipla Limited | 1:24-cv-01287.)
